MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

Financial Performance - MediWound reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of$ 0.59, and compared to a loss of $0.19 per share a year ago, indicating an earnings surprise of 38.98% [1] - The company posted revenues of$ 5.84 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.53% and showing an increase from year-ago revenues of $5.34 million [2] - Over the last four quarters, MediWound has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - MediWound shares have increased approximately 8.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$ 0.56 on revenues of $5.25 million, and for the current fiscal year, it is -$ 2.39 on revenues of $24.98 million [7] Industry Outlook - The Medical - Drugs industry, to which MediWound belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]